SciBase Holding AB (publ)
STO:SCIB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
SciBase Holding AB (publ)
Other Non-Cash Items
SciBase Holding AB (publ)
Other Non-Cash Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Non-Cash Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SciBase Holding AB (publ)
STO:SCIB
|
Other Non-Cash Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Elekta AB (publ)
STO:EKTA B
|
Other Non-Cash Items
kr1.6B
|
CAGR 3-Years
165%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
CellaVision AB
STO:CEVI
|
Other Non-Cash Items
kr789k
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
N/A
|
|
|
Getinge AB
STO:GETI B
|
Other Non-Cash Items
-kr562m
|
CAGR 3-Years
-85%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Arjo AB (publ)
STO:ARJO B
|
Other Non-Cash Items
-kr12m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Stille AB
STO:STIL
|
Other Non-Cash Items
-kr83k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
52%
|
CAGR 10-Years
15%
|
|
SciBase Holding AB (publ)
Glance View
SciBase Holding AB is a global medical technology company, which engages in the development and sale of instruments for the detection of skin cancer and other skin diseases. The company is headquartered in Sundbyberg, Stockholm and currently employs 23 full-time employees. The company went IPO on 2015-06-02. The firm specializes in the manufacture of point of care device, called Nevisense, which is aimed to detect of malignant melanoma. Nevisense analyze suspicious lesions by using Electrical Impedance Spectroscopy (EIS) which is applied as an electrical signal to the skin. The diagnostic product is sold in Nordic countries, Belgium, Germany, Great Britain and Australia.
